Akèy › Maladi Crohn › Indiana
Etid klinik pou Maladi Crohn nan Indiana
13 etid pou Maladi Crohn ap chèche patisipan nan sit nan Indiana.
Vil nan Indiana
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Indiana University Health University Hospital ( Site 5022), Indianapolis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284145, New Albany
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Indiana University Health University Hospital /ID# 278129, Indianapolis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- IU Health University Hospital, Indianapolis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Riley Hospital for Children, Indianapolis
Ap rekriteFaz 3
Laj 3 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06663332Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 23, 2026 · NCT05995353A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Riley Childrens Hospital, Indianapolis
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 24, 2026 · NCT05509777Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 24, 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Riley Hospital for Children at Indiana University Health, Indianapolis
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152Precise Infliximab Exposure and Pharmacodynamic Control
- Riley Hospital for Children, Indianapolis
Ap rekriteFaz 2/3
Laj 6 a 22 · Tout sèks · Mizajou May 5, 2026 · NCT05660746Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.